Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has reportedly seen the resignation and retirement of its president, Liu Yongjun. The company’s research and development initiatives are now under the leadership of Innovent’s founder, chairman, and CEO, De-Chao Micheal Yu.
Dr. Liu, a distinguished scholar with a PhD in Internal Medicine from Norman Bethune Medical University and a PhD in Immunology from the University of Birmingham’s Medical School in the UK, brings a wealth of expertise to his roles. His academic pursuits were complemented by postdoctoral training at the University of Birmingham. With over three decades of experience in the biopharmaceutical sector, Dr. Liu has made significant contributions to oncology and immunology.
His illustrious career includes tenures as a senior scientist at Schering Plough, Chief Scientific Officer and Global Research Leader at Medimmune—AstraZeneca’s subsidiary—and Global Research Leader at Sanofi. Dr. Liu’s appointment at Innovent Bio in October 2020 saw him overseeing the company’s global R&D, pipeline strategy, business collaboration, and international expansion efforts.- Flcube.com
